A Phase II Study Of Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Latest Information Update: 25 Sep 2024
At a glance
- Drugs Fludarabine (Primary) ; Ibrutinib (Primary) ; Pembrolizumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 19 Sep 2024 Planned End Date changed from 31 Dec 2026 to 31 Dec 2025.
- 11 Sep 2024 Results investigating the effect of PD-1 blockade in patients with CLL, we performed scRNA-seq and paired scTCR-seq on enriched CD8+ T cells from longitudinal blood samples of 4 CLL patients during treatment with pembrolizumab and ibrutinib from this clinical trial presented at the CRI-ENCI: 8th Annual International Cancer, Immunotherapy Conference.
- 09 Nov 2023 Planned End Date changed from 31 Dec 2030 to 31 Dec 2026.